Objective: To study the characteristics of multiple sclerosis (MS) in a series of Jordanian patients observed at the Beta-Interferon Committee and compare them with those from other Arab/Middle Eastern or Western countries.
Introduction
Multiple sclerosis (MS) is a disease of the central nervous system of unknown etiology. 1 middle adulthood, after trauma, in Western countries. 2 MS has an unequal distribution worldwide, 3, 4 and it affects approximately one million young adults, mostly women, worldwide. 5 It is known to show variable prevalence rates, demographic and clinical manifestations depending on geography and ethnic background. 1 It is generally believed that MS prevalence is low in Middle Eastern countries. 6 Many studies about MS came from Arab countries. 7 Therefore, this study was done with the aim of delineating the characteristics of MS in Jordan, including incidence, geographic distribution, age of onset/ gender ratio, clinical presentation, and MRI features, MS pattern and use of Betainterferon. Results will be compared with those from other Arab/Middle Eastern and Western countries.
Methods
Beta-interferon is fully covered by the medical insurance of the Jordanian Ministry of Health(MOH) for all classes of Jordanians. Due to its high cost, the MOH decided to establish a National MS Beta-interferon Committee in 2002 (which will be referred to as the 'committee'), including 4 neurologists from the public sector, with the aim of applying international criteria for the use of Beta-interferon. Up to this date, 450 patients referred from the private and public sectors(except military-insured patients) are receiving Beta-interferon through this 'committee', which is still functional. The patients were referred either from 3 major MOH hospitals(one in the capital Amman, one in Irbid in the North of the country, and one in Karak in the South), one major university hospital in Amman, or from neurologists in the private sector.
Following the signature on a consent form, information was collected from a predesigned data sheet including the patient's age/gender, place of birth, actual area of residence in Jordan, date of the onset of symptoms, number/type/date of relapses, disease duration, MS pattern/course, Expanded Disability Status Scale (EDSS) 8 11 The acute relapse was defined according to Poser's criteria as an acute onset of new symptoms or signs or worsening of previous symptoms for more than 24 hours, preceded by stability for at least 6 weeks in the absence of metabolic cause such as fever. 12 The patients were evaluated at one stage of their illness (either early after onset or after a few years). The diagnosis was based on McDonald's criteria. 9 Inclusion criteria for the use of Beta-interferon were for patients above the age of 12 years, who were clinically stable (namely, either not in relapse or having had a relapse before at least 3 months), and they were enrolled if they had at least 2 relapses in the preceding 2 years and were ambulatory with an EDSS of 0 to 5. 8 We also included CIS The most common clinical manifestations are shown in table 2. The mean number of relapses was 1.8 with a 0.6 relapse/year. We noticed a relatively high number of cases of CIS (28 patients) and among them 14 were monofocal, i.e., MS affecting only one organ system at onset, and 14 multifocal affecting more than one organ system. Among the 14 patients with monofocal CIS, 6 had motor symptoms, 3 sensory, 4 optic neuritis, and one with diplopia. The mean EDSS score at presentation was 2.6 (range 0-5.5), with the majority (81 patients) having an EDSS between 0 and 3. Table 3 small peaks in June and October (7 and 6 patients, respectively). In total, Beta-interferon was used in 81 patients. Among 66 patients with RR MS, Beta-interferon was used in 62 (Beta-interferon 1 b in 30 and Beta-interferon 1 a in 32), not being used in the remaining 4 because they had a recent relapse prior to the visit to the MS committee with an EDSS score above 5.
Among 28 patients with CIS MS, Betainterferon was used in 19.It was not used in the remaining 9 because they had less than 4 MRI brain/spinal cord lesions. None of the patients with SP MS or PP MS received Betainterferon.
Discussion
Several points emerge from this study of 101 Jordanian MS patients seen over a one-yearperiod at the National MS Beta-Interferon committee.
The mean age of onset in our patients was 27.1 yrs with a peak incidence in the 3 rd decade, similar to studies from other Arab countries, These were not referred to the 'committee' because they were not candidates for Beta-interferon. Thus, this study is not representative of the MS population in Jordan as a whole. Almost 1/3 of our patients (28 patients) had a clinically isolated syndrome, much higher than the 6.9% found in a Lebanese study. 22 This is mostly due to the referral bias to the 'committee'.
The mean EDSS score at presentation in our patients was 2.6, comparable with another Jordanian study. 19 The mean duration from the disease onset to the assessment by the 'committee' was 3.3 yrs, with half of our patients (50 out of 101) having a short duration of illness of less than 1 year and only 5% a long duration (more than 15 yrs), much shorter than in another study from Iraq (mean 7.25 yrs, range 1-28 yrs). 23 This due to a better recognition of the disease because of the presence of better diagnostic facilities, especially MRI, but might also be explained by the referral bias to the 'committee'. 46 Another study from Kuwait on 89 MS cases found a focus of high incidence and another possible north-south gradient in Palestine, a country neighboring to Jordan. 39 Our study showed a trend toward an increase in the number of newly diagnosed MS cases in the last decade (89 cases) compared to the previous one (11 cases) and also an increase in the number of new cases in 2009 (34 cases) compared with the previous years within the same decade (see table 3 ). This might be explained by the fact that a large proportion of MS cases diagnosed before 2000 have already progressed to the secondary progressive stage, and thus they were not referred to the 'committee', which was established in 2002, because they were considered by their primary physician as not eligible for Beta-Interferon. An overall prevalence rate of 32/100000 was reported in Jordan in 1993, 16 whereas in 1977, it was reported as 7/100000. 47 This apparent increase might be due to improving access to neurological care, increased awareness of MS among the public and health professionals, change in the diagnostic criteria with better diagnostic facilities (role of MRI), and in the actual study, a referral bias. Nevertheless, it may indicate a real increase in the incidence of MS in Jordan. 17 These reports of increased prevalence are partially attributed to a genuine increase in the incidence of the disease. Over the past 20 years, there have also been multiple reports of increased frequency of MS worldwide. 48, 49 In addition, a genuine increase in the incidence of MS has been reported in several areas of the United States and Canada. 
